Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma?
Polatuzumab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new first-line therapy option for patients with advanced stage diffuse large B-cell lymphomas (DLBCL). The survival benefit was seen only in a subgroup of patients with non-bulky disease and activated B cell (ABC) subtype. Educating clinicians about the efficacy and safety profile of this novel combination regimen as well as the disease characteristics that will derive a survival benefit is essential for shared decision making while selecting the optimal first-line therapy.
Target Audience
This program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this program, participants should be able to:
- Summarize the evidence from clinical trials supporting the use of Pola-R-CHP for patients with newly diagnosed diffuse large B-cell lymphomas.
- Develop an individualized treatment plan for patients with newly diagnosed diffuse large B-cell lymphoma based on disease characteristics and cell of origin.
Jeremy S. Abramson, MD, MMSc
Mass General Cancer Center
David A. Russler-Germain, MD, PhD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Jeremy S. Abramson, MD, MMSc
AstraZeneca Pharmaceuticals LP: Honoraria
BeiGene: Consulting Fee; Honoraria
Bristol Myers Squibb: Consulting Fee; Grant/Research Support; Honoraria
Cellectar: Consulting Fee
Cellectis: Grant/Research Support
Eli Lilly and Company: Consulting Fee
Epizyme, Inc.: Consulting Fee
Foresight Diagnostics: Consulting Fee
Genentech, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Incyte Corporation: Honoraria
Interius BioTherapeutics, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Regeneron Pharmaceuticals: Grant/Research Support
Roche Laboratories, Inc.: Consulting Fee
SeaGen: Consulting Fee; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support
David A. Russler-Germain, MD, PhD
AstraZeneca Pharmaceuticals LP: Consulting Fee
Cartography Biosciences: Consulting Fee
Regeneron Pharmaceuticals: Consulting Fee
Congress Planning Committee Disclosures
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Gabriela S. Hobbs, MD
AbbVie, Inc.: Scientific Advisor
Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences, Inc.: Consulting Fee
Incyte Corporation: Grant/Research Support; Scientific Advisor
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pfizer Inc.: Consulting Fee
PharmaEssentia USA Corporation: Consulting Fee
Regeneron Pharmaceuticals: Equity Interest/Stock Options
Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol-Myers Squibb: Grant/Research Support; Scientific Advisor
CARsgen Therapeutics: Grant/Research Support
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Moderna, Inc.: Consulting Fee
Oricell Therapeutics: Grant/Research Support
Pfizer Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor
Bernard L. Marini, PharmD, BCOP
Servier: Consulting Fee
MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Consulting Fee; Honoraria
Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Scientific Advisor
ADC Therapeutics: Scientific Advisor
Amgen Inc.: Consulting Fee
Arvinas: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Consulting Fee
Eli Lilly and Company: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour, 0.75 of which are pharmacotherapeutic contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-24-129-H01-P
PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until December 1, 2025. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 ANCC Pharmacology Contact Hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing